SCHEMBL4566795

SCHEMBL4566795

Cn1c(=O)c(-c2cc(N)ccc2Cl)cc2cnc(Cl)cc21

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SRC P12931 13/20 0.55
FGFR1 P11362 11/20 0.55
ABL1 P00519 4/20 0.44
EGFR P00533 1/20 0.44
FGFR2 P21802 1/20 0.44
FGFR4 P22455 1/20 0.44
FGFR3 P22607 1/20 0.44
PDGFRB P09619 2/20 0.42
PDGFRA P16234 2/20 0.42
MAPK14 Q16539 2/20 0.42
KIT P10721 1/20 0.42
WEE1 P30291 2/20 0.40
CDC7 O00311 1/20 0.39
CDK2 P24941 1/20 0.39
BRPF1 P55201 1/20 0.39
SIK1 P57059 1/20 0.38
SIK2 Q9H0K1 1/20 0.38
SIK3 Q9Y2K2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL502110 0.89 SRC (0.51) SRCFGFR1ABL1EGFRFGFR2
SCHEMBL5046332 0.86 SRC (0.51) SRCFGFR1ABL1EGFRFGFR2
SCHEMBL5057537 0.86 FGFR1 (0.67) SRCFGFR1ABL1SIK1SIK2
SCHEMBL21990261 0.83 FGFR1 (0.58) SRCFGFR1ABL1EGFRFGFR2
SCHEMBL4420929 0.81 SRC (0.50) SRCFGFR1ABL1EGFRFGFR2
SCHEMBL24666947 0.77 FGFR1 (0.70) SRCFGFR1ABL1EGFRFGFR2
SCHEMBL5061776 0.77 FGFR1 (0.48) SRCFGFR1EGFRFGFR2FGFR4
SCHEMBL29977716 0.77 FGFR1 (0.70) SRCFGFR1ABL1EGFRFGFR2
SCHEMBL17119622 0.76 SRC (0.53) SRCFGFR1ABL1EGFRFGFR2
SCHEMBL4424326 0.76 FGFR1 (0.67) SRCFGFR1ABL1EGFRFGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE48731-E1 Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2021-09-14 US disclosed
EP-3722296-A2 DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC (US) 2020-10-14 EP disclosed
EP-3366293-B1 DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS LLC (US) 2020-03-11 EP disclosed
EP-3366293-A1 DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC (US) 2018-08-29 EP disclosed
EP-2858646-B1 DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS LLC (US) 2017-12-20 EP disclosed
US-20150320759-A1 DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC 2015-11-12 US disclosed
US-8940756-B2 Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC 2015-01-27 US disclosed
US-20140088075-A1 DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, INC. (US) 2014-03-27 US disclosed
US-8461179-B1 Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2013-06-11 US disclosed
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 US disclosed
EP-2063897-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 EP disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US disclosed
WO-2008034008-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC. (US) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150320759-A1 DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES NME1, DCK, NME2 SRC 715/4885FGFR1 376/4885ABL1 72/4885
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 SRC 417/4885FGFR1 577/4885ABL1 936/4885
US-20140088075-A1 DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES NME1, DCK, NME2 SRC 715/4885FGFR1 376/4885ABL1 72/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 SRC 417/4885FGFR1 577/4885ABL1 936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.